Search results

The High Performance Macromolecular Crystallography beamline will enable the study of very small (sub-5 micrometre) or weakly diffracting crystals, providing a state-of-the-art high-throughput facility for researchers. MX3 will be able to study the structures of large proteins and protein complexes for virology, drug design and industrial applications via goniometer mounted crystals, in-tray screening, or via serial crystallography methods.

The Australian Centre for Neutron Scattering (ACNS) is a major research facility for neutron science that comprises a suite of neutron instruments with a range of techniques for scientific investigations in physics, chemistry, materials science, medicine and environmental science among other fields.

Four international authorities will deliver plenary addresses virtually at the 15th International Conference on Accelerator Mass Spectrometry (AMS15) , which will be held online from 15-19 November.

On behalf of ANSTO thank you for your interest in our tours. We hope your visit to ANSTO will be both enjoyable and informative.

Frequently asked questions about ANSTO for the community.

ANSTO has provided supporting experimental evidence of a highly unusual quantum state, a quantum spin liquid (QSL), in a two-dimensional material.

Research reports for the first time how solid methane and nitrogen expand in response to temperature changes and resolves an historic ambiguity relating to the structure of nitrogen.

Detailed data on ANSTO electricity use and CO2 emissions for FY2024 - FY2025

ANSTO's OPAL reactor is one of the world's most advanced and reliable research reactors today. To ensure we can continue operating OPAL safely and reliably and maximise utilisation, ANSTO must regularly carry out maintenance and upgrades.

ANSTO shared expertise on next-generation reactors and nuclear power with sustainable energy experts at the Australian Academy of Science symposium in May.

Guide to successful proposals and experiments at the Powder Diffraction beamline.

ANSTO is proud to announce that a license has been issued by the Therapeutic Goods Administration to produce Lutetium-177 (Lu-177) for use in clinical trials.

Recent catastrophic Australian bushfires produced extremely high levels of fine particle pollution.

In April 15, 1953, Australia entered the nuclear science arena, when the Atomic Energy Act came into effect. The Australian Atomic Energy Commission (AAEC) followed and in 1987 the AAEC evolved into the Australian Nuclear Science and Technology Organisation (ANSTO) as it’s known today.